News
The Tobacco Exclusion That's Distorting Every Psychosis-Prevention Trial You're Running
4+ hour, 26+ min ago (1371+ words) The Clinical Trial Vanguard The Tobacco Exclusion That's Distorting Every Psychosis-Prevention Trial You're Running She was 21, Spanish-monolingual, referred from a community mental health clinic in Anaheim with a structured interview confirming attenuated psychotic symptoms and a SOPS score that put…...
Positive Phase 2 B Results for Treatment-Resistant Depression
10+ mon, 3+ week ago (92+ words) Atai Life Sciences and Beckley Psytech announced positive topline results from a Phase 2b trial of BPL-003 (intranasal mebufotenin) for treatment-resistant depression (TRD). Both 8mg and 12mg single doses showed statistically significant reductions in depressive symptoms compared to a low-dose control, with effects…...
The IT Neuron Finding That Should Reshape How We Design Rapid-Acting Depression Trials
1+ week, 6+ day ago (741+ words) The Clinical Trial Vanguard The IT Neuron Finding That Should Reshape How We Design Rapid-Acting Depression Trials A patient I've been treating for three years " treatment-resistant MDD, two failed SSRIs, one failed SNRI, buprenorphine-maintained for co-occurring opioid use disorder " finally…...
First Patient Dosed in Tamarind Trial for MDD
10+ mon, 1+ week ago (55+ words) HMNC Brain Health and Spruce Biosciences have dosed the first patient in the Phase 2 TAMARIND clinical trial. This trial is investigating tildacerfont, a CRF1 receptor antagonist, as a treatment for Major Depressive Disorder (MDD) in patients selected using HMNC's investigational patient selection…...
The GLP-1 Mood Signal Is Real " But So Is the Psychiatric Worsening Risk
2+ mon, 3+ hour ago (1047+ words) The Clinical Trial Vanguard The GLP-1 Mood Signal Is Real " But So Is the Psychiatric Worsening Risk A pattern I've been tracking across my dual-diagnosis patient panel this year: the patients who come in asking about semaglutide are not the…...
Minerva Presents Safety Trial Data on Roluperidone, Olanzapine
2+ mon, 5+ day ago (556+ words) The Clinical Trial Vanguard Minerva Presents Safety Trial Data on Roluperidone, Olanzapine Minerva Neurosciences reported that an open-label safety study of roluperidone coadministered with olanzapine showed no clinically significant adverse effects and no meaningful PK or PD interactions. The company…...
Emerging Data on Brilaroxazine for Schizophrenia Symptoms
6+ mon, 3+ week ago (685+ words) Reviva will present new analyses on negative symptoms with brilaroxazine from its Phase 3 RECOVER double'blind trial in acutely exacerbated schizophrenia and from a one'year open'label extension in clinically stable patients at CNS Summit 2025 in Boston. The poster, "Brilaroxazine Treatment Effect…...
Seclidemstat's Role in LSD1 Inhibition Validated in Oncology Studies
10+ mon, 3+ week ago (385+ words) Salarius Pharmaceuticals announced positive preclinical data on its LSD1 inhibitor, seclidemstat, and provided an update on its merger with Decoy Therapeutics. Two recently published animal studies reinforce the potential of LSD1 inhibition in treating various cancers. Simultaneously, Salarius continues to progress toward…...